Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
ObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedot...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582939642167296 |
|---|---|
| author | Daiki Ikarashi Tatsuya Kawamura Keita Ogasawara Yumeka Arakawa Arisa Machida Ayato Ito Ei Shiomi Shigekatsu Maekawa Renpei Kato Mitsugu Kanehira Jun Sugimura Wataru Obara |
| author_facet | Daiki Ikarashi Tatsuya Kawamura Keita Ogasawara Yumeka Arakawa Arisa Machida Ayato Ito Ei Shiomi Shigekatsu Maekawa Renpei Kato Mitsugu Kanehira Jun Sugimura Wataru Obara |
| author_sort | Daiki Ikarashi |
| collection | DOAJ |
| description | ObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedotin for advanced urothelial carcinoma. We also evaluated the periods of tumor shrinkage maintenance (the period when best response was maintained) and regrowth (the period from best response to tumor growth confirmation) between primary and metastatic organs.ResultsMeasurable metastatic organs included the lung in 17, lymph node in 22, liver in 6, and bone in 5 cases. Primary lesion was detected in 20 cases. The mean tumor shrinkage rates for lung, lymph node, liver, and bone metastases and primary sites were 21% (−212 to 100), 13% (−130 to 86), −8.5% (−158 to 85), −64% (−250 to 21), and 22% (−38 to 79), respectively. The tumor shrinkage was maintained for 5.9 (0.7–14) months in lung metastases, 8.3 (2.6–14.5) months in lymph node metastases, 3.6 months in liver metastases, 0.7 months in bone metastases, and 1.8 (0.7–5.4) months in primary sites, and the period of regrowth was 7.3 (2.2–19.4), 4.8 (2.0–8.9), 2.8, 6.5, and 2.5 (1.1–5.9) months, respectively.ConclusionsEnfortumab vedotin showed significant tumor shrinkage in the primary tumor, lung metastases, and lymph node metastases, whereas the durability of tumor shrinkage was limited in the primary tumor. |
| format | Article |
| id | doaj-art-40adda83b5364e168d78d139ad47baa8 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-40adda83b5364e168d78d139ad47baa82025-01-29T05:21:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14939221493922Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organsDaiki IkarashiTatsuya KawamuraKeita OgasawaraYumeka ArakawaArisa MachidaAyato ItoEi ShiomiShigekatsu MaekawaRenpei KatoMitsugu KanehiraJun SugimuraWataru ObaraObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedotin for advanced urothelial carcinoma. We also evaluated the periods of tumor shrinkage maintenance (the period when best response was maintained) and regrowth (the period from best response to tumor growth confirmation) between primary and metastatic organs.ResultsMeasurable metastatic organs included the lung in 17, lymph node in 22, liver in 6, and bone in 5 cases. Primary lesion was detected in 20 cases. The mean tumor shrinkage rates for lung, lymph node, liver, and bone metastases and primary sites were 21% (−212 to 100), 13% (−130 to 86), −8.5% (−158 to 85), −64% (−250 to 21), and 22% (−38 to 79), respectively. The tumor shrinkage was maintained for 5.9 (0.7–14) months in lung metastases, 8.3 (2.6–14.5) months in lymph node metastases, 3.6 months in liver metastases, 0.7 months in bone metastases, and 1.8 (0.7–5.4) months in primary sites, and the period of regrowth was 7.3 (2.2–19.4), 4.8 (2.0–8.9), 2.8, 6.5, and 2.5 (1.1–5.9) months, respectively.ConclusionsEnfortumab vedotin showed significant tumor shrinkage in the primary tumor, lung metastases, and lymph node metastases, whereas the durability of tumor shrinkage was limited in the primary tumor.https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/fulldurabilityenfortumab vedotinprimarymetastatic organtumor shrinkage |
| spellingShingle | Daiki Ikarashi Tatsuya Kawamura Keita Ogasawara Yumeka Arakawa Arisa Machida Ayato Ito Ei Shiomi Shigekatsu Maekawa Renpei Kato Mitsugu Kanehira Jun Sugimura Wataru Obara Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs Frontiers in Oncology durability enfortumab vedotin primary metastatic organ tumor shrinkage |
| title | Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs |
| title_full | Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs |
| title_fullStr | Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs |
| title_full_unstemmed | Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs |
| title_short | Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs |
| title_sort | tumor shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs |
| topic | durability enfortumab vedotin primary metastatic organ tumor shrinkage |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/full |
| work_keys_str_mv | AT daikiikarashi tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT tatsuyakawamura tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT keitaogasawara tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT yumekaarakawa tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT arisamachida tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT ayatoito tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT eishiomi tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT shigekatsumaekawa tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT renpeikato tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT mitsugukanehira tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT junsugimura tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans AT wataruobara tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans |